Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Trial Profile

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms ATTAIN
  • Most Recent Events

    • 18 Aug 2017 Status changed from active, no longer recruiting to discontinued due to poor accrual.
    • 01 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 02 Jul 2015 Planned primary completion date changed from 1 Aug 2019 to 1 Jul 2019 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top